Further supporting this notion, the IL1 receptor antagonist, which potently inhibits IL1β/IL1r1 signaling, was recently found to be ineffective at reducing pain in the treatment of women with chronic fatigue syndrome, which has also been linked to insufficient peripheral perfusion [75]. The gene discussed is IL1R1; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.